RxDoctor Payments Data

Mark Burket, MD

Cardiovascular Disease · Perrysburg, OHNPI 1750375887

Payments from drug & device makers

$104,003in general payments, 2019–2025

Across 139 payments — averaging $748.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Surmodics, Inc.$74K
  • Biotronik Inc.$13K
  • Boston Scientific$12K
  • Cook Research Incorporated$5K
  • Kestra Medical Technology Services, Inc.$315
  • Inari Medical, Inc.$143
  • plus $519 from 7 others
$13,405in research payments, 2019–2025

Across 9 payments — averaging $1489.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Inspiremd Ltd$10K
  • Cook Research Incorporated$4K

What the payments were for

  • Speaking & faculty fees$7,25053%
  • Travel & lodging$5,49340%
  • Food & beverage$9777%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$104,003 in reported general payments places this provider in the 85th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$80,361
Medicare patients
364
Services billed
648

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban54$58,143
XareltoRivaroxaban34$53,475
EntrestoSacubitril/Valsartan15$16,547
Prasugrel Hcl28$5,318
ClopidogrelClopidogrel Bisulfate262$2,916
Atorvastatin Calcium204$2,226
Cilostazol97$1,796
Amiodarone Hcl16$1,621
Metoprolol Succinate69$1,143
Diltiazem 24hr Er (Cd)Diltiazem Hcl23$774
Lisinopril73$640
Chlorthalidone22$536
Warfarin Sodium31$485
Metoprolol Tartrate79$478
Carvedilol44$407

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$109$53,47534 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Perrysburg

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →